Morphic reports results from EMERALD-1 Phase 2a study of MORF-057

Morphic Therapeutic reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the alpha4beta7 integrin, in adults with moderate to severe ulcerative colitis. "In EMERALD-1, patients with moderate-to-severe ulcerative colitis receiving MORF-057 experienced a statistically significant reduction in the RHI score and a 25.7% clinical remission rate as measured by the mMCS. In addition, MORF-057 was generally well tolerated in EMERALD-1 with no safety signal observed. We are emboldened by these positive results and excited to continue to enroll the ongoing EMERALD-2 Phase 2b study," commented Praveen Tipirneni, MD, Chief Executive Officer of Morphic Therapeutic. "I couldn’t be more thankful to these patients and investigators, and proud of our team for advancing MORF-057 much closer to our goal of providing a safe and effective treatment option for IBD patients, in pill form." The main cohort of the EMERALD-1 open-label, single-arm Phase 2a trial of MORF-057 enrolled 35 patients. In the trial, MORF-057 achieved the primary endpoint, demonstrating a statistically significant reduction in the RHI score of 6.4 points from baseline to week 12. In the prespecified secondary endpoint, change in modified Mayo Composite Score, patients had a 2.3-point reduction from baseline. In the study, patients receiving MORF-057 experienced a 25.7% remission rate according to mMCS.